Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2025-10-29 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the change in the company's registered capital and the corresponding amendment to the company's articles of association (公司章程). It details the increase in share capital due to the vesting of restricted stock and the specific changes to the articles of association reflecting the new capital and share count. The document is issued by the board and is a formal public announcement of these changes. It does not contain financial statements, audit information, or detailed financial performance data. It is not a report itself but an announcement of corporate governance changes related to capital and articles of association. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2025-10-29 Chinese
益方生物科技（上海）股份有限公司章程（2025年10月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 益方生物科技（上海）股份有限公司 (InventisBio Co., Limited). It includes chapters on general provisions, business scope, share issuance, shareholder rights, board of directors, senior management, financial accounting, audit, notices and announcements, mergers, and amendments to the charter. The content is legal and governance-related, focusing on company structure, shareholder meetings, board responsibilities, share issuance and transfer rules, and internal governance mechanisms. There is no financial performance data, earnings information, or audit report results. It is not a report of financial results or an announcement of voting results. The document is a governance document detailing the company's internal rules and governance practices, consistent with the definition of Governance Information (CGR). The document length is substantial and contains the full text of the governance charter, not just an announcement or summary.
2025-10-29 Chinese
益方生物2025年第三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled as the "2025 Third Quarter Report" of 益方生物科技（上海）股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheet, profit and loss statement, and cash flow statement for the first nine months of 2025. The report includes comprehensive financial data and analysis for the quarter, such as revenue, profit, earnings per share, and cash flows. It explicitly states it is unaudited and covers the third quarter period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not a brief announcement or a certification letter, nor is it an annual report or earnings release. Therefore, the correct classification is IR with high confidence. 9M 2025
2025-10-29 Chinese
益方生物关于召开2025年第三季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会), including the date, time, location, participants, and how investors can participate and ask questions. It explicitly states that the company will release the 2025 Q3 report on October 30, 2025, and the meeting is to discuss that report. The document does not contain actual financial data or the report itself, but rather is a notice about the upcoming earnings call/meeting. The document length is short (1454 characters), and it serves as an announcement for the earnings explanation meeting rather than the earnings release or the full quarterly report. Therefore, the best classification is Call Transcript (CT) because it is about the earnings explanation meeting, which is a form of conference call or investor interaction event. However, since this document is only the announcement of the meeting and not the transcript itself, it is more appropriate to classify it as Regulatory Filings (RNS) as a general regulatory announcement about the earnings call meeting. The document is not a full transcript, nor is it the earnings release (ER) or interim report (IR). Given the options, RNS is the best fit for this announcement of the earnings explanation meeting.
2025-10-28 Chinese
益方生物关于诉讼事项进展的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from a company regarding the progress and final judgment of a legal dispute involving patent infringement and technical secret claims. It details the litigation stages, court decisions, involved parties, and financial implications of the lawsuit. The text includes references to court rulings, dates of hearings, and the final outcome that the appeal was dismissed and the original judgment upheld. There is no financial data, earnings information, or report publication mentioned. The content is clearly about legal proceedings and their impact on the company. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is 2195 characters, which is typical for an announcement rather than a full report, but the detailed legal content and case description confirm it is a legal proceedings update rather than a simple announcement or regulatory filing.
2025-09-29 Chinese
益方生物关于2022年限制性股票激励计划预留授予部分第二个归属期归属结果暨股票上市公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and registration of shares related to a 2022 restricted stock incentive plan for the company 益方生物科技（上海）股份有限公司. It details the decision-making process, share quantities, registration dates, and impact on share capital. The document includes references to board meetings, supervisory board meetings, and regulatory approvals related to the stock incentive plan. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of share issuance and registration related to stock incentives. This fits best under the category of Share Issue/Capital Change (SHA), as it concerns new shares issued under a stock incentive plan and their registration and listing. The document length is about 4944 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is SHA with high confidence.
2025-09-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.